Treatment Outcomes of Patients Switching From an Injectable Drug to Bedaquiline During Short Standardized Treatment for Multidrug-resistant Tuberculosis in Mozambique.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 30901021.
- Also identified by DOI 10.1093/cid/ciz196.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bedaquiline was recommended by the World Health Organization as the preferred option in treatment of multidrug-resistant tuberculosis (MDR-TB) with long regimens. However, no recommendation was given for the short MDR-TB regimen. Data from our small cohort of patients who switched from injectable drug to bedaquiline suggest that a bedaquiline-based short regimen is effective and safe.
Medical subject headings
- Antitubercular Agents
- Diarylquinolines
- Drug Substitution
- Tuberculosis, Multidrug-Resistant